CCI
VKTX icon

Columbus Circle Investors’s Viking Therapeutics VKTX Stock Holding History

Columbus Circle Investors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-358,777
Closed -$3.57M – 182
2019
Q1 		$3.57M Sell
358,777
-294,027
-45% -$2.46M 0.09% 124
2018
Q4 		$4.99M Buy
652,804
+310,551
+91% +$3.71M 0.14% 118
2018
Q3 		$5.96M Buy
+342,253
New +$4.07M 0.12% 145

Other funds holding VKTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Columbus Circle Investors's VKTX Position: Q2 2019 in Review

Columbus Circle Investors sold out of Viking Therapeutics (VKTX) in Q2 2019, closing a stake of 358,777 shares — an estimated $3.57M sold.

Columbus Circle Investors first reported a position in VKTX in Q3 2018 and held it in 3 quarters. The position peaked at $5.96M in Q3 2018. 156 funds tracked by Wall St. Rank hold VKTX as of Q2 2019.

  • Columbus Circle Investors reported no remaining Viking Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Columbus Circle Investors sold 358,777 Viking Therapeutics shares in Q2 2019, an estimated $3.57M.
  • Columbus Circle Investors first reported a position in Viking Therapeutics in Q3 2018 and held it in 3 quarters.
  • Columbus Circle Investors's Viking Therapeutics position peaked at $5.96M in Q3 2018.
  • 156 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2019.

Based on Columbus Circle Investors's 13F filing for Q2 2019, filed 2 Aug 2019.